{"company":{"id":3786145,"name":"celldex","domain":"celldex.com","url":"https://alion.io/company/celldex"},"section":"news","answer":"celldex: 9 headlines on record, 7 headlines in the last 90 days. Its story counts 1 milestone.","figures":[{"label":"Headlines","value":"9"},{"label":"In 90 days","value":"7"},{"label":"Milestones","value":"1"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":9},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":1}],"news":[{"date":"2026-09-24","kind":"Press release","title":"Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX)","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/CLDX/pressreleases/4774318/canaccord-genuity-sticks-to-their-buy-rating-for-celldex-cldx/"},{"date":"2026-09-24","kind":"Press release","title":"Barclays Sticks to Their Buy Rating for Celldex (CLDX)","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/CLDX/pressreleases/4771980/barclays-sticks-to-their-buy-rating-for-celldex-cldx/"},{"date":"2026-09-23","kind":"News","title":"Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/celldex-cldx-overcome-heavy-burn-124142562.html"},{"date":"2026-09-22","kind":"News","title":"Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/celldex-phase-iii-csu-trials-160254116.html?fr=sycsrp_catchall"},{"date":"2026-09-22","kind":"News","title":"Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/celldex-announces-positive-results-from-phase-3-embarq-csu1-and-embarq-csu2-studies-of-barzolvolimab-which-met-primary-and-all-key-secondary-endpoints-1036563342"},{"date":"2026-09-22","kind":"News","title":"Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials","source":"thepharmaletter.com","url":"https://thepharmaletter.com/biotech-news/celldex-s-barzolvolimab-hits-primary-and-secondary-endpoints-in-twin-phase-iii-csu-trials"},{"date":"2026-09-22","kind":"News","title":"Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition","source":"fiercebiotech.com","url":"https://fiercebiotech.com/biotech/celldex-redeems-monoclonal-antibody-pair-phase-3-wins-chronic-skin-condition"},{"date":"2026-05-07","kind":"News","title":"Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4900153-celldex-stock-mast-cell-reset-story-hiding-inside-a-csu-trial"},{"date":"2025-11-14","kind":"News","title":"LB Pharmaceuticals, Celldex hire commercial chiefs as launch plans ramp up","source":"fiercepharma.com","url":"https://fiercepharma.com/marketing/lb-and-celldex-hire-commercial-chiefs-launch-plans-ramp"}],"story":[{"title":"Founded"}],"as_of":"2026-11-16","cite":"celldex, News. Alion, Nov 16, 2026. https://alion.io/company/celldex/news","html_url":"https://alion.io/company/celldex/news","json_url":"https://alion.io/company/celldex/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T07:08:00Z"}}